Table 3 Performance of various screening strategies
Sensitivity TP/(TP + FN) 95% CI | Specificity TN/(TN + FP) 95% CI | Negative Predictive Value TN/(TN + FN) | Negative likelihood ratio Point estimate 95% CI | Positive Predictive Value TP/(TP + FP) | Positive likelihood ratio Point estimate 95% CI | |
|---|---|---|---|---|---|---|
Venous 75 g OGTTa | 1 18/(18 + 0) (0.82–1) | 1 598/(598 + 0) (0.99–1) | 1 598/(598 + 0) | n/a | 1 (18/18 + 0) | n/a |
POC RBG ≥ 7 mmol/L (126.0 mg/dL) | 0.17 3/(3 + 15) (0.06–0.39) | 0.97 581/(581 + 17) (0. 95–98) | 0.97 581/(581 + 15) | 0.86 (0.70–1.1) | 0.15 3/(3 + 17) | 5.86 (1.89–18.23) |
POC 1 h 50 g ≥ 7.8 mmol/L (140.4 mg/dL) | 0.44 8/(8 + 10) (0.25–0.66) | 0.79 470/(470 + 128) (0.75–0.82) | 0.98 470/(470 + 10) | 0.71 (0.47–1.07) | 0.06 8/(8 + 128) | 2.08 (1.21–3.56) |
POC 1 h 50 g ≥ 7.2 mmol/L (129.6 mg/dL) | 0.56 10/(10 + 8) (0.34–0.75) | 0.64 382/(382 + 216) (0.60–0.67) | 0.98 382/(382 + 8) | 0.70 (0.41–1.17) | 0.04 10/(10 + 216) | 1.54 (1.00–2.36) |
Venous FBG ≥ 5.1 (91.8 mg/dL) | 0.78 14/(14 + 4) (0.55–0.91) | 1 598/(598 + 0) (.99–1) | 0.99 598/(598 + 4) | n/a | 1 14/(14 + 0) | 0.22 (0.09–0.53) |
POC FBG ≥ 5.1 mmol/L (91.8 mg/dL) | 0.33 6/(6 + 12) (0.16–0.56) | 0.95 567/(567 + 31) (0.93–0.96) | 0.98 567/(567 + 12) | 0.70 (0.51–0.98) | 0.16 6/(6 + 31) | 6.43 (3.08–13.45) |
POC 75 g OGTT | 0.56 10/(10 + 8) (0.34–0.75) | 0.91 542/(542 + 56) (0.88–0.93) | 0.99 542/(542 + 8) | 0.49 (0.29–0.82) | 0.15 10/(10 + 56) | 5.93 (3.66–9.61) |
POC HbA1c ≥ 6.5% | 0.22 4/(4 + 14) (0.09–0.45) | 0.99 592/(592 + 6) (0.98–0.99) | 0.98 592/(592 + 14) | 0.79 (0.61–1.01) | 0.4 4/(4 + 6) | 22.15 (6.84–71.72) |
Venous HbA1c ≥ 6.5% | 0.11 2/(2 + 16) (0.03–0.33) | 0.99 591/(591 + 7) (0.98–0.99) | 0.97 591/(591 + 16) | 0.90 (0.76–1.06) | 0.22 2/(2 + 7) | 9.49 (2.12–42.54) |